Adoptive immunotherapy for posttransplantation viral infections.

[1]  C. Rooney,et al.  Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. , 2004, Blood.

[2]  P. Moss,et al.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003, The Lancet.

[3]  J. Michálek,et al.  Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. , 2003, Blood.

[4]  M. Mayes,et al.  Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  G. Papanicolaou,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  F. Watzinger,et al.  Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. , 2003, Blood.

[7]  B. Yeap,et al.  Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Mackensen,et al.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.

[9]  A. Davis,et al.  Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy , 2003, Journal of immunotherapy.

[10]  M. Boeckh,et al.  Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  A. Davis,et al.  Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. , 2003, Blood.

[12]  S. Riddell,et al.  Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. , 2003, Blood.

[13]  J. Romagnoli,et al.  Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy. , 2003, Journal of hematotherapy & stem cell research.

[14]  P. Hwu,et al.  Dual-specific T cells combine proliferation and antitumor activity , 2002, Nature Biotechnology.

[15]  M. Schilham,et al.  High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Fegan,et al.  Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. , 2002, Blood.

[17]  J. Michálek,et al.  Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. , 2002, Cytotherapy.

[18]  A. Foster,et al.  Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  A. Fischer,et al.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study , 2002, The Lancet.

[20]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[21]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[22]  A. Fischer,et al.  Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. , 2002, Human Gene Therapy.

[23]  Paul Martin,et al.  A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.

[24]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[25]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[26]  J. Melo,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. , 2002, Blood.

[27]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[28]  Zhensheng Liu,et al.  Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals1 , 2002, The Journal of Immunology.

[29]  A. Rickinson.  Epstein-Barr virus. , 2001, Virus research.

[30]  P. Henslee-Downey,et al.  Epstein–Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation , 2001, Bone Marrow Transplantation.

[31]  P. Ljungman.  Respiratory virus infections in stem cell transplant patients: the European experience. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.

[33]  N. Hensel,et al.  Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. , 2001, Blood.

[34]  J. Garcia,et al.  In Vitro Generation of Epstein-Barr Virus–Specific Cytotoxic T Cells in Patients Receiving Haplo-Identical Allogeneic Stem Cell Transplantation , 2001, Journal of immunotherapy.

[35]  N. Kapoor,et al.  Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  G. Sandford,et al.  Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  T. Clackson,et al.  A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. , 2001, Blood.

[38]  Jaap M Middeldorp,et al.  Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. , 2001, Blood.

[39]  C. Craddock,et al.  Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. , 2001, Blood.

[40]  M. Peuchmaur,et al.  Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children , 2001, Bone Marrow Transplantation.

[41]  R. Collins,et al.  Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[42]  S. Mackinnon,et al.  Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. , 2001, Blood.

[43]  C. Sample,et al.  An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. , 2001, Blood.

[44]  G. Nolan,et al.  Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. , 2001, Clinical immunology.

[45]  H. Einsele,et al.  Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. , 2001, Blood.

[46]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[47]  B. Walker,et al.  Characterization of a Novel Respiratory Syncytial Virus-Specific Human Cytotoxic T-Lymphocyte Epitope , 2000, Journal of Virology.

[48]  Q. Sun,et al.  A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. , 2000, Human gene therapy.

[49]  M. Sadelain,et al.  Rapid selection of antigen-specific T lymphocytes by retroviral transduction. , 2000, Blood.

[50]  Michel Sadelain,et al.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells , 2000, Nature Biotechnology.

[51]  Zhensheng Liu,et al.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.

[52]  I. Ernberg,et al.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.

[53]  W. Britt,et al.  Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. , 1999, Blood.

[54]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[55]  V. Calcaterra,et al.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.

[56]  I. Alexander,et al.  Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro , 1999, Gene Therapy.

[57]  D. Czerwinski,et al.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  J. Tarrand,et al.  Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  H. Heslop,et al.  Adenovirus infection after pediatric bone marrow transplantation , 1999, Bone Marrow Transplantation.

[60]  C. Rooney,et al.  Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. , 1998, Human gene therapy.

[61]  K. Cornetta,et al.  Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. , 1998, Blood.

[62]  G. Hale,et al.  Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. , 1998, Blood.

[63]  P. Ljungman.  Immune reconstitution and viral infections after stem cell transplantation. , 1998, Bone marrow transplantation.

[64]  M. Boeckh,et al.  Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. , 1997, Blood.

[65]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[66]  H. Heslop,et al.  Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .

[67]  H. Einsele,et al.  Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease , 1997, Bone Marrow Transplantation.

[68]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[69]  MD Janet A. Englund,et al.  Respiratory Viral Infections in Immunocompetent and Immunocompromised Persons , 1997, The American Journal of Medicine.

[70]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[71]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[72]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[73]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[74]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[75]  R. Krance,et al.  Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease , 1995, British journal of haematology.

[76]  J. Hurwitz,et al.  Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. , 1994, Transplantation.

[77]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[78]  K. Cornetta,et al.  Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. , 1994, Blood.

[79]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[80]  W. Wold,et al.  Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. , 1991, Virology.

[81]  G. Winberg,et al.  GENETIC VARIABILITY OF ADENOVIRUSES * , 1980, Annals of the New York Academy of Sciences.

[82]  K. Lucas,et al.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts , 2004, Springer Seminars in Immunopathology.

[83]  N. Khan.  Adoptive cellular therapy for early CMV infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003 .

[84]  S. Mackinnon,et al.  Clinical trials with CMV-specific T cells. , 2002, Cytotherapy.

[85]  H. Heslop,et al.  Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[86]  D. Schendel,et al.  Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant , 2001, Bone Marrow Transplantation.

[87]  L. Swinnen,et al.  Diagnosis and treatment of transplant-related lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  V. Leblond,et al.  Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  Y. Oki,et al.  Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation , 2000, Bone Marrow Transplantation.

[90]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[91]  A. Dalgleish.  Viruses and cancer. , 1991, British Medical Bulletin.

[92]  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8 (cid:1) T cells , 2022 .